DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited., [Objectives] HIV infection has been associated with lower rates of sustained viral response (SVR) with direct-acting antivirals (DAAs). There are few data on glecaprevir/pibrentasvir (G/P) in HIV/HCV coinfection outside clinical trials., [Methods] The HEPAVIR-DAA cohort, which recruits HIV/HCV-coinfected patients (NCT02057003) and the GEHEP-MONO cohort (NCT02333292), including HCV-monoinfected individuals, are two concurrent ongoing multicentre cohorts of patients receiving anti-HCV treatment. Patients starting G/P included in those cohorts were analysed. Overall SVR (ITT), discontinuations due to adverse effects, and dropouts were evaluated and compared between both cohorts., [Results] Of the 644 patients who started G/P with evaluable SVR, 132 were HIV/HCV coinfected. Overall SVR rates were 487/512 (95.1%) in HCV-monoinfected patients versus 126/132 (95.5%) in HIV/HCV-coinfected patients (P = 1.000). One patient (0.8%) relapsed, and another (0.8%) discontinued treatment due to side effects. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected versus HCV-monoinfected patients. The main reason for not reaching SVR among HIV/HCV-coinfected patients was premature dropout linked to active drug use., [Conclusions] G/P in HIV/HCV coinfection was highly effective and tolerable in clinical practice. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected compared with HCV-monoinfected patients but active drug use is still a barrier to reach HCV microelimination., This study has been funded by Instituto de Salud Carlos III through the project ‘PI018/00606’ and co-funded by the European Regional Development Fund/European Social Fund ‘A way to make Europe/Investing in your future’. This work was supported by the Ministry of Science, Innovation and Universities of Spain for A.G.S, who is recipient of a Miguel Servet Research Contract (CP18/00146), co-financed by the FSE ‘El Fondo Social Europeo invierte en tu futuro’. A.C.G. has received a Rıo Hortega grant from the Instituto de Salud Carlos III (CM19/00251) and a research extension grant Acción B, Acción para el Refuerzo de la Actividad Investigadora en las Unidades Clínicas del Servicio Andaluz de Salud 2021, Clínicos Investigadores (grant number B-0061-2021). J.M. has received a research extension grant Acción A, Acción para el Refuerzo anual de la Actividad Investigadora en las Unidades Clínicas del Servicio Andaluz de Salud 2021 (grant number A1-0060-2021). This research was supported by CIBER-Consorcio Centro de Investigación Biomédica en Red-(CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea–NextGenerationEU; Fundación para la Investigación en Salud (FIS) del Instituto Carlos III (PI22/01098, PI21/00793 and PI18/01270). DC-M is the recipient of a Rio Hortega grant by the Carlos III Health Institute (Instituto de Salud Carlos III-ISCIII) (CM22/00176)., Peer reviewed